Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis

Archana Vijayakumar, Ayse Okesli‐Armlovich, Ting Wang, Isabel Olson, Minji Seung, Saritha Kusam, David Hollenback, Sangeetha Mahadevan, Bruno Marchand, Maria Toteva, David G. Breckenridge, James L. Trevaskis, Jamie Bates – 22 June 2022 – Dysregulated hepatocyte lipid metabolism is a hallmark of hepatic lipotoxicity and contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH).

Implementation of a controlled human infection model for evaluation of HCV vaccine candidates

Eleanor Barnes, Graham S. Cooke, Georg M. Lauer, Raymond T. Chung – 22 June 2022 – Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral (DAA) drugs have transformed the treatment of HCV. However, it has become clear that, without an effective HCV vaccine, it will not be possible to meet the World Health Organization targets of HCV viral elimination. Promising new vaccine technologies that generate high magnitude antiviral T and B cell immune responses and significant new funding have recently become available, stimulating the HCV vaccine pipeline.

Low‐dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation

Christian E. Oberkofler, Dimitri A. Raptis, Philip C. Müller, Richard X. Sousa da Silva, Kuno Lehmann, Takahiro Ito, Timothy Owen, Joerg‐Matthias Pollok, Alessandro Parente, Andrea Schlegel, Peregrina Peralta, Erin Winter, Markus Selzner, Margot Fodor, Manuel Maglione, Manuel Jaklitsch, Hugo P. Marques, Mariana Chavez‐Villa, Alan Contreras, Philipp Kron, Peter Lodge, Scott Alford, Abbas Rana, Paolo Magistri, Fabrizio Di Benedetto, Bethany Johnson, Varvara Kirchner, Francis Bauldrick, Karim J. Halazun, Omid Ghamarnedjad, Arianeb Mehrabi, Samanta Teixeira Basto, Eduardo S. M.

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas – 22 June 2022

Multicenter study of racial and ethnic inequities in liver transplantation evaluation: Understanding mechanisms and identifying solutions

Alexandra T. Strauss, Carolyn N. Sidoti, Tanjala S. Purnell, Hannah C. Sung, John W. Jackson, Scott Levin, Vedant S. Jain, Daniel Malinsky, Dorry L. Segev, James P. Hamilton, Jacqueline Garonzik‐Wang, Stephen H. Gray, Macey L. Levan, Joseph R. Scalea, Andrew M. Cameron, Ahmet Gurakar, Ayse P. Gurses – 20 June 2022 – Racial and ethnic disparities persist in access to the liver transplantation (LT) waiting list; however, there is limited knowledge about underlying system‐level factors that may be responsible for these disparities.

Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications

Ka‐Hei Lam, Stephanie Ma – 20 June 2022 – Cancer stem cells (CSCs) are now recognized as one of the major root causes of therapy failure and tumor recurrence in hepatocellular carcinoma (HCC). Early studies in the field focused primarily on the intrinsic regulators of CSC maintenance, but in recent years, mounting evidence has demonstrated the presence and role of extrinsic regulators in the tumor microenvironment (TME) in the control of liver CSCs.

Acute portal hypertension using portal vein ligation abrogates TRAIL expression of liver‐resident NK cells

Yuki Imaoka, Koki Sato, Masahiro Ohira, Kouki Imaoka, Takuya Yano, Ryosuke Nakano, Yuka Tanaka, Hideki Ohdan – 19 June 2022 – The effects of acute portal hypertension (PHT), which is reported as poor prognostic factors in patients with hepatocellular carcinoma, are not well known on the liver immune system, including natural killer (NK) cells. The aim of this study, therefore, was to investigate how acute PHT influences the functions and characteristics of liver‐resident NK (lr‐NK) cells using an acute PHT mouse model.

Subscribe to